Advertisement

Gastric Cancer

, Volume 22, Issue 6, pp 1226–1237 | Cite as

The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis

  • Beate RauEmail author
  • Andreas Brandl
  • Peter Thuss-Patience
  • Fabian Bergner
  • Wieland Raue
  • Alexander Arnold
  • David Horst
  • Johann Pratschke
  • Matthias Biebl
Original Article

Abstract

Background

Patients with peritoneal metastases of gastric cancer have a poor prognosis and median survival of 7 months. This study compared treatment options and outcomes based on the Peritoneal Cancer Index (PCI).

Methods

This retrospective analysis included patients with gastric cancer treated between August 2008 and December 2017 with synchronous peritoneal metastases only diagnosed by laparoscopy. The three treatments were as follows: (1) cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with pre- and postoperative systemic chemotherapy (n = 58), (2) laparotomy/laparoscopy without CRS, but HIPEC in combination with pre- and postoperative systemic chemotherapy (n = 11), and (3) systemic chemotherapy only (n = 19).

Results

A total of 88 patients aged 54.6 ± 10.9 years with mean PCI of 14.3 ± 11.3 were included. The PCI was significantly lower in group 1 (8.3 ± 5.7) than in group 2 (23.9 ± 11.1, p < 0.001) and group 3 (27.3 ± 9.3, p < 0.001). Mean time from diagnosis to laparoscopy was 5.2 ± 2.9 months. The median overall survival was 9.8 ± 0.7 for group 1, 6.3 ± 3.0 for group 2 and 4.9 ± 1.9 months for group 3 (p < 0.001). Predictors for deteriorated overall patient survival included > 4 cycles of preoperative chemotherapy (HR 4.49, p < 0.001), lymph-node metastasis (HR 3.53, p = 0.005), PCI ≥ 12 (HR 2.11, p = 0.036), and incompleteness of cytoreduction (HR 4.30, p = 0.001) in patients treated with CRS and HIPEC.

Conclusion

CRS and HIPEC showed convincing results in selected patients with PCI < 12 and complete cytoreduction. Prolonged duration (> 4 cycles) of preoperative intravenous chemotherapy reduced patient survival in patients suitable for CRS and HIPEC.

Keywords

Peritoneal metastases Gastric cancer Hyperthermic intraperitoneal chemotherapy Cytoreductive surgery Preoperative chemotherapy 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consent or substitute for it was obtained from all patients included in the study.

References

  1. 1.
    Gretschel S, Siegel R, Estevez-Schwarz L, Hunerbein M, Schneider U, Schlag PM. Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg. 2006;93(12):1530–5.  https://doi.org/10.1002/bjs.5513.CrossRefGoogle Scholar
  2. 2.
    Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7.CrossRefGoogle Scholar
  3. 3.
    Esaki Y, Hirayama R, Hirokawa K. A comparison of patterns of metastasis in gastric cancer by histologic type and age. Cancer. 1990;65(9):2086–90.CrossRefGoogle Scholar
  4. 4.
    Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V, et al. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin—a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15:73.  https://doi.org/10.1186/s12885-015-1081-8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2013;11(5):531–46.CrossRefGoogle Scholar
  6. 6.
    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608–18.  https://doi.org/10.1002/cncr.25356.CrossRefPubMedGoogle Scholar
  7. 7.
    Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2(2):85–97.  https://doi.org/10.4251/wjgo.v2.i2.85.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefGoogle Scholar
  9. 9.
    Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7.  https://doi.org/10.1245/s10434-010-1039-7.CrossRefPubMedGoogle Scholar
  10. 10.
    Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.  https://doi.org/10.1200/JCO.2007.13.9378.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.  https://doi.org/10.1016/S0140-6736(10)61121-X.CrossRefGoogle Scholar
  12. 12.
    Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708.  https://doi.org/10.1016/s1470-2045(16)30531-9.CrossRefGoogle Scholar
  13. 13.
    Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.  https://doi.org/10.1200/jco.2010.33.0597.CrossRefGoogle Scholar
  14. 14.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.  https://doi.org/10.1056/nejmoa055531.CrossRefGoogle Scholar
  15. 15.
    Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521–30.  https://doi.org/10.1002/cncr.11660.CrossRefPubMedGoogle Scholar
  16. 16.
    Imamoto H, Oba K, Sakamoto J, Iishi H, Narahara H, Yumiba T, et al. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer. 2011;14(1):81–90.  https://doi.org/10.1007/s10120-011-0016-6.CrossRefPubMedGoogle Scholar
  17. 17.
    Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661–5.  https://doi.org/10.1016/j.ejso.2006.03.007.CrossRefPubMedGoogle Scholar
  18. 18.
    Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311–6.  https://doi.org/10.1002/jso.21324.CrossRefPubMedGoogle Scholar
  19. 19.
    Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338–44.  https://doi.org/10.1245/s10434-017-6047-4.CrossRefPubMedGoogle Scholar
  20. 20.
    Takeshita K, Liu Y, Ishibashi H, Yonemura Y. Laparoscopic hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosisfrom gastric cancer: its beneficial effects on reduction and exact evaluation of the peritoneal cancer index. Am Surg. 2017;83(11):1315–20.PubMedGoogle Scholar
  21. 21.
    Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367–73.  https://doi.org/10.1007/s11605-015-2995-9.CrossRefPubMedGoogle Scholar
  22. 22.
    Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147–52.  https://doi.org/10.1245/s10434-013-3443-2.CrossRefPubMedGoogle Scholar
  23. 23.
    Yoshida M, Sugino T, Kusafuka K, Nakajima T, Makuuchi R, Tokunaga M, et al. Peritoneal dissemination in early gastric cancer: importance of the lymphatic route. Virchows Arch. 2016;469(2):155–61.  https://doi.org/10.1007/s00428-016-1960-7.CrossRefPubMedGoogle Scholar
  24. 24.
    Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol. 2016;34(23):2721–7.  https://doi.org/10.1200/jco.2015.65.7692 (http://www.jco.org. Author contributions are found at the end of this article).
  25. 25.
    Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg. 2011;35(3):684–92.  https://doi.org/10.1007/s00268-010-0891-8.CrossRefPubMedGoogle Scholar
  26. 26.
    An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7(1):38–51.  https://doi.org/10.1016/j.apsb.2016.09.002.CrossRefPubMedGoogle Scholar
  27. 27.
    Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE, Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 2012;38(3):226–34.  https://doi.org/10.1016/j.ctrv.2011.06.005.CrossRefPubMedGoogle Scholar
  28. 28.
    Yang W, Ma J, Zhou W, Cao B, Zhou X, Yang Z, et al. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer. Expert Opin Ther Targets. 2017;21(11):1063–75.  https://doi.org/10.1080/14728222.2017.1389900.CrossRefPubMedGoogle Scholar
  29. 29.
    Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan Y, et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle. 2015;14(15):2473–83.  https://doi.org/10.1080/15384101.2015.1005530.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kurokawa Y, Hamakawa T, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, et al. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer. Anticancer Res. 2015;35(4):2223–8.PubMedGoogle Scholar
  31. 31.
    Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 Trial. JAMA Oncol. 2017;3(9):1237–44.  https://doi.org/10.1001/jamaoncol.2017.0515.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003;6(3):159–67.  https://doi.org/10.1007/s10120-003-0245-4.CrossRefPubMedGoogle Scholar
  33. 33.
    Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, et al. Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol. 2017;8(6):1018–25.  https://doi.org/10.21037/jgo.2017.08.13.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49(12):3380–4.PubMedGoogle Scholar
  35. 35.
    Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.  https://doi.org/10.1245/s10434-011-1631-5.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Rau B. Prospective multicentric phase III study. Z Gastroenterol. 2014;52(3):262.CrossRefGoogle Scholar
  37. 37.
    Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, et al. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol. 2015;26(2):332–9.  https://doi.org/10.1093/annonc/mdu542.CrossRefPubMedGoogle Scholar
  38. 38.
    Fukuhara S, Yabe M, Montgomery MM, Itagaki S, Brower ST, Karpeh MS Jr. Race/ethnicity is predictive of lymph node status in patients with early gastric cancer. J Gastrointest Surg. 2014;18(10):1744–51.  https://doi.org/10.1007/s11605-014-2590-5.CrossRefPubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  1. 1.Department of Surgery, Campus Virchow-Klinikum and Charité Campus MitteCharité-Universitätsmedizin BerlinBerlinGermany
  2. 2.Medical Clinic for Hematology, Oncology and Tumor-Immunology, Campus Virchow-KlinikumCharité-Universitätsmedizin BerlinBerlinGermany
  3. 3.Department of General, Visceral and Thoracic SurgeryAKH CelleCelleGermany
  4. 4.Institute of PathologyCharité-Universitätsmedizin BerlinBerlinGermany

Personalised recommendations